FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 32350104 Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Benz Edward J. JR	Requiring	acte of Event quiring Statement nth/Day/Year) 26/2021 3. Issuer Name and Ticker or Trading Symbol Candel Therapeutics, Inc. [CADL]						
(Last) (First) (Middle) C/O CANDEL THERAPEUTICS,	I		Relationship of Reporting Person(s) to Issuer (Check all applicable)			5. If Amendment, Date of Original Filed (Month/Day/Year)		
INC. 117 KENDRICK ST., SUITE 450	_		X Director Officer (give title below)	10% Owner Other (specify below)		6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person		
(Street) NEEDHAM MA 02494	_							oy More than One Person
(City) (State) (Zip)								
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	Form: D (D) or Ir			lature of Indirect Beneficial nership (Instr. 5)	
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise		Form:	6. Nature of Indirect Beneficial Ownership (Instr.
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security		Direct (D) or Indirect (I) (Instr. 5)	5)
Stock Option (Right to Buy)	(1)	04/05/2027	Common Stock	32,548	1.46		D	
Stock Option (Right to Buy)	(2)	08/17/2028	Common Stock	4,068	1.46		D	
Stock Option (Right to Buy)	(3)	12/14/2030	Common Stock	16,274	1.55		D	
Stock Option (Right to Buy)	(3)	06/23/2031	Common Stock	16,274	6.64		D	

Explanation of Responses:

- 1. This option shall vest and become exercisable in four substantially equal annual installments, with the first installment vested on October 4, 2018.
- 2. 25% of this option vested and became exercisable on May 28, 2019, with an additional 25% vesting on January 1, 2020 and the remainder vesting in 36 substantially equal monthly installments thereafter.
- 3. This option is fully vested and exercisable as of the date hereof.

Remarks:

/s/ Edward J. Benz, Jr.

07/26/2021

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 $Note: File \ three \ copies \ of \ this \ Form, \ one \ of \ which \ must \ be \ manually \ signed. \ If \ space \ is \ insufficient, \ see \ Instruction \ 6 \ for \ procedure.$

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.